1. Home
  2. Bills
  3. S. 415

S. 415 · 117th Congress · 2021–2022

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.

S. 415 in the 117th Congress (2021–2022) became law — introduced on Feb 24, 2021, sponsored by Bill Cassidy with 2 co-sponsors.

During the 117th Congress (2021–2022), Joe Biden was president, and Democrats held the House majority and Republicans the Senate majority.

Status
Became law
Introduced
Feb 24, 2021
Co-sponsors
2
Policy area
Health
Public law
Public Law 117-9

What it does

This bill provides statutory authority for the existing Food and Drug Administration (FDA) practice of defining active ingredient more narrowly as active moiety in certain situations, such as when determining whether a new drug is entitled to a market exclusivity period or providing priority review of drugs for treating rare pediatric diseases.

Summary by the nonpartisan Congressional Research Service.

Sponsor

Bill Cassidy (R-LA). Co-sponsors: 1 Democrat, 1 Republican.

Where it stands

  • IntroducedFeb 24, 2021
  • Passed the SenateMar 10, 2021
  • Passed the HouseApr 14, 2021
  • Sent to the PresidentApr 20, 2021
  • Became lawApr 23, 2021

Latest action: Became Public Law No: 117-9. (Apr 23, 2021)

Other Health bills in the 117th Congress

Committees

More

From GovInfo bill records, Congressional Research Service summaries, Voteview roll calls and lobbying reports.

Cite or embed this page

Capitol Receipts, “S. 415 (117th Congress): A bill to amend the Federal Food, Drug, and…,” https://www.capitolreceipts.com/bill/117-s-415/a-bill-to-amend-the-federal-food-drug-and (accessed 2026-10-17).